Climb Bio Highlights Two Antibody Programs at Wells Fargo Conference

At the Wells Fargo 21st Annual Healthcare Conference, Climb Bio (CLYM) underscored its two antibody development programs as key drivers of its growth strategy, targeting unmet needs in IgA nephropathy and membranous nephropathy. The company reported $239 million in cash reserves as of Q2 2025, extending its runway through the second half of 2028, following a $110 million PIPE financing in late April 2025. Management highlighted its lead candidate, CLYM116, a proprietary APRIL-only monoclonal antibody with a 12-week dosing regimen, aiming for IgA suppression exceeding 50%—a depth not achieved by first-generation therapies, which typically reduce IgA by around 50%. Early-phase data in healthy volunteers demonstrated robust suppression of free APRIL, with maintenance dosing set at 400 mg/m². Meanwhile, Budoprutug, a CD19-targeting antibody, showed promising Phase I-B results in membranous nephropathy, achieving a 60% complete renal response in five patients, including full B-cell depletion and sustained remission in three of five cases. In immune thrombocytopenia (ITP), the 250 mg cohort outperformed benchmark BTK/SYK inhibitors with over 50% durable platelet response. The company plans to present Phase II data for IgA nephropathy by year-end 2025 and Phase II pMN results in 2026, with potential pivotal trials for both programs pending regulatory feedback. With a U.S. IgA nephropathy patient population estimated at 200,000 and a market exceeding $20 billion, Climb Bio’s dual pipeline positions it to capitalize on rising demand for disease-modifying therapies in nephrology and hematology.